OxySure Systems, Inc.

About Us

OxySure Systems, Inc. is a Frisco, Texas-based medical technology company that focuses on the design, manufacture and distribution of specialty medical and respiratory solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure’s products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other public settings.

Quotes

OxySure strongly disagrees with both the content and import of the FDA's March 29, 2016, safety notice about the OxySure Model 615 device. We are sure that the thousands of people saved over the years with our product also disagree. Notably, the notice cites no evidence that shows that the OxySure Model 615 device does not perform up to FDA standards, or that it fails to perform as intended -- indeed, the record of usage to save lives would suggest otherwise. We continue to stand by our product, its innovativeness and the value it brings to society. FDA's sudden and unprompted notice is not only full of inaccuracies; it is plainly arbitrary and capricious.

Mazin Sbaiti, Esq., attorney with Friedman & Feiger LLP and OxySure’s litigation counsel

The Board is reviewing all strategic and operational options at its disposal.

Julian Ross, Chairman of the Company

From a strategic standpoint, we like the idea of using this opportunity to take a step back, take Model 615 offline and accelerate our plans for Generation 2. We are evaluating this approach being done in combination with an outsourcing strategy. Outsourcing can provide the benefits of immediate scale, efficiency and approvals such as ISO 13485, which is needed for markets such as Canada and others. At the same time, it can lower cost and it makes manufacturing cost more variable.

Julian Ross, Chairman of the Company

This is the first in a series of steps we are executing relative to the implementation of our e-retail strategy. And our e-retail strategy complements our distribution and sales operations very well as they focus on developing offline solutions for our institutional customers. We are already working on our next stellar online property.

Julian Ross, CEO

Our entire sales team is fired up and the race has already begun.

Julian Ross, CEO

We are looking forward to a bumper month and everyone will have fun in the process.

Julian Ross, CEO

You miss 100% of the shots you don’t take.

Michael Jordan

We are grateful for the support we have received from the FEDC and we are proud of the manufacturing capability our facility now has to offer. We look forward to leveraging our platform as we continue to expand our business.

Julian Ross, CEO, OxySure Therapeutics

The Frisco EDC is glad to see the continued growth of OxySure Therapeutics, Inc. as a home-grown company that graduated from Frisco’s NTEC business accelerator,” said Jim Gandy, President of the Frisco EDC. “We wish OxySure continued success in growing the company.

Jim Gandy, President, Frisco EDC

We have already closed several deals under leasing programs with MedOne and our customers love the easy, fast and flexible approach. In addition, our customers can now enjoy several other benefits when they purchase their lifesaving medical equipment from us, including conservation of capital and tax advantages.

Julian Ross, CEO

We are delighted to have Zach join our team, and we very much look forward to working together to grow our business, enhance shareholder value, improve medical outcomes with our innovative products, and save lives.

Julian Ross, Chairman and CEO of OxySure

I am pleased to join the OxySure Advisory Board and I look forward to assisting Julian and his team as they develop this business globally. I believe OxySure is a game changer and a no-brainer as a companion product to Automated External Defibrillators (AEDs) for post-resuscitation usage by lay rescuers in cardiac arrest events. I also believe patients with unstable angina, asthma, pulmonary fibrosis and severe anaphylactic reactions like peanut allergy could benefit from OxySure prior to the arrival of first responders.

Dr. Zach Zachariah

This has been a good building quarter for us. We were able to bring strong management to the opportunities and challenges along the way and we are pleased with the exemplary results.

Julian T. Ross, CEO

Looking forward, we remain on track with the launch of at least one new solution in 2015,” added Ross. “Also, we have started working with our medical advisors on laying the ground work for our direct to consumer campaign addressing “At Risk” markets such as Asthma and Immunology markets.

Julian T. Ross, CEO

We expect to continue our efforts to grow our direct sales force. We have made additional progress and will be continuing our work on the Nasdaq uplisting process. Finally, our growth plan is working and our investments are paying dividends. We are especially excited about working towards one of our next key milestones, which is to reach the $10 million revenue run rate number and break even some time in 2016.

Julian T. Ross, CEO

Said Al Ford, Cardiac Science General Manager and Senior Vice President of Sales / Marketing: “We are excited about our relationship with OxySure. The OxySure Model 615 is a great companion product to our AEDs, and we intend to work together closely to address the significant market need to improve outcomes in sudden cardiac arrest, which is the nation’s No. 1 killer, claiming approximately 369,000 lives every year.”

Al Ford

Speaking at a joint sales launch of the new Cardiac Science Powerheart® G5 AED in Frisco, Texas, recently, Clark Hood, Vice President of Resuscitation Sales for OxySure, stated: “We are pleased with the mutual cooperation we have enjoyed with Cardiac Science so far; and we look forward to the continued strengthening of this relationship as we market and sell our lifesaving products together.”

Clark Hood

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

OxySure Announces 2011 Fiscal Year Financial Results

Fri, Mar 30, 2012 23:14 CET

Maintains net loss of $.10 per share on 21.3% lower SG&A during IPO yearFrisco, Texas, March 30, 2012 – OxySure® Systems, Inc. (OTCBB:OXYS) (“OxySure,” or the “Company”), today reported a slightly narrower net loss of $1,532,399, or $0.10 per diluted share, for fiscal year 2011 compared to a net loss of $1,578,957, or $0.10 per diluted share, for fiscal year 2010. The slightly narrower loss was driven by a decrease of $311,689 in selling, general and administrative expenses. “We are pleased that we were able to contain our costs in a year that marks our Company entering the public

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Quotes

OxySure Announces 2011 Fiscal Year Financial Results

Media